Web Exclusives – May 19, 2022
Multiple myeloma is a relatively rare form of blood cancer that affects plasma cells, which are immune cells that produce antibodies.
Web Exclusives – May 17, 2022
Skin cancer is the most common cancer in the United States. Other than sunscreen, many people are unaware of additional ways they can protect themselves and prevent skin cancer.
Web Exclusives – April 19, 2022
Among the complex causes for the disparities in cancer outcomes, lacking or insufficient health insurance plays a major role. Good insurance coverage contributes to earlier diagnosis and improved treatment for patients with different types of cancers.
Web Exclusives – March 15, 2022
Doctors and nurses are heroes for the care they provide, and researchers are heroes for the breakthrough treatments and medications they develop. Let us not overlook the incredible contributions of oncology social workers in the journey of a patient with cancer.
Nutrition & Cancer
Web Exclusives – February 8, 2022
Based on current and evolving scientific evidence, the cancer prevention guidelines have been shifting from a nutrient-centric approach to a more holistic approach of diet that is characterized as dietary patterns.
World Cancer Day
Web Exclusives – February 4, 2022
Cancer affects all races, ethnicities, sexual orientations, genders, and nationalities.
Web Exclusives – January 13, 2022
Cervical cancer during pregnancy can be successfully managed with a multidisciplinary treatment team and an individualized treatment strategy that optimizes maternal treatment while considering fetal safety.
FDA Approvals, News & Updates
Web Exclusives – December 21, 2021
On November 22, 2021, the FDA approved Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound); from Aadi Bioscience) for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid-cell tumor (PEComa), a rare type of mesenchymal tumors that can occur in any part of the body.
FDA Approvals, News & UpdatesImmunotherapy
Web Exclusives – December 14, 2021
On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options.